In several studies, RRM1 levels were found to be inversely correlated with tumor response to gemcitabine treatment [25–28], and increased RRM1 expression was associated with gemcitabine resistance in various cell lines [29, 30]. The gene discussed is RRM1; the disease is neoplasm.